Counterfeit Wegovy and Ozempic: How to Tell If Yours Is Real in 2026

On June 20, 2024, the WHO put out Medical Product Alert N°6/2024 — its first global alert on falsified semaglutide — after fake Ozempic batches turned up in pharmacy supply chains in Brazil, the UK and the US. The agency does not issue these often. When it does, it usually means the same product is already moving through more than one continent's distribution system and has been for months.

By the time you read this, 2024–2026 has produced one of the busiest enforcement stretches in modern injectable drug history. The FDA has seized counterfeit Ozempic three separate times since August 2023, the most recent batch including thousands of units across multiple states. The MHRA in the UK, BfArM in Germany and FAMHP in Belgium have all issued falsified semaglutide notices. Singapore's HSA has run multiple advisories. Hong Kong's Drug Office has hospitalized patients who injected pens that turned out to contain no semaglutide at all. Korea's MFDS has banned overseas direct purchase of GLP-1s entirely since October 2024. Japan's PMDA is dealing with imported semaglutide for off-label cosmetic use as a growing problem. China's NMPA has prosecuted illegal manufacturers. Saudi SFDA and UAE MOHAP have run public-awareness campaigns.

If you have a Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda or local-brand GLP-1 in your refrigerator right now, the question is not whether counterfeits exist. They do, in volume. The question is whether the specific box in front of you is one of them — and how to tell before you press the button on a pen that might be filled with insulin, saline or contaminated tap water.

What the regulators have actually done since 2023

The pattern is consistent across agencies. Counterfeit pens get into the legitimate wholesale chain — usually through a single grey-market distributor or a stolen-and-resold lot — and then surface at retail pharmacies that had no reason to suspect them.

The FDA's August 2023 seizure was the first big one. The agency, working with Novo Nordisk, recovered thousands of units of counterfeit Ozempic 1 mg pens from the US supply chain. December 2023 brought a second seizure, larger than the first. Through 2024 and into 2025, additional batches were found, some testing positive for bacterial contamination — a sterility failure that turns a routine injection into a sepsis risk.

WHO's June 20, 2024 alert formalized what national agencies were already chasing. Three confirmed countries at announcement (Brazil, UK, US), with the agency strongly implying the actual list was longer. The alert specifically warned that some falsified products had been "lawfully obtained from authorised suppliers" downstream of the breach point. Translation: the pharmacist did not know.

A short timeline of regulatory action since 2023:

• August 2023 — FDA first US seizure of counterfeit Ozempic.
• December 2023 — FDA second seizure, multi-state distribution.
• Throughout 2023–2024 — MHRA (UK), BfArM (Germany), FAMHP (Belgium) issue national falsified-semaglutide alerts.
• June 20, 2024 — WHO Medical Product Alert N°6/2024 published.
• 2024 — Singapore HSA runs multiple counterfeit GLP-1 advisories.
• 2024 — Hong Kong Drug Office seizes "Ozempic" pens with zero semaglutide content; hospital admissions reported.
• October 2024 — Korea MFDS bans overseas direct purchase of GLP-1 medications.
• 2024–2025 — China NMPA prosecutes multiple illegal semaglutide manufacturers.
• 2024–2025 — Brazil ANVISA expands counterfeit Ozempic warnings.
• 2024–2025 — Saudi SFDA and UAE MOHAP launch consumer awareness campaigns on counterfeit Ozempic, Saxenda and Wegovy.
• 2024–2026 — Japan PMDA flags rising imports of semaglutide for off-label cosmetic weight loss.

The throughline: counterfeiters target whatever brand has the longest pharmacy queue. In 2023 that was Ozempic. By 2024 it was Wegovy. Mounjaro and Zepbound joined the target list as soon as US allocation tightened. The molecule changes; the playbook does not.

WHO Alert N°6/2024 was the first global flag, but it was not the first event. National agencies had been tracking grey-market semaglutide for at least nine months before WHO formalized the warning. If your pharmacy is downstream of a wholesaler who was not paying attention in 2023, the question is what else got through.

Country and region matrix — what is approved, what is being faked, what to look up

Brand names matter because counterfeiters copy specific brands. A fake "Ozempic" box in a country where the legitimate brand is sold as 诺和泰 is a near-instant tell. A fake Wegovy box in a country where Wegovy is not yet officially launched is another.

Two patterns to notice. First, the countries with the most aggressive enforcement — US, UK, Germany, Korea, Singapore — are also the countries where legitimate supply was tightest in 2023–2024, because that is where shortages created the demand vacuum counterfeiters fill. Second, every market on the list has a national lookup tool. Almost no patients use them.

How to verify the prescription in your hand is real

The goal is not paranoia. It is a five-minute checklist before you inject. Counterfeit pens are sometimes obvious, sometimes nearly perfect — but they almost always fail at least one of the checks below.

Start at the box, then the pen, then the supply chain.

Box-level checks (Novo Nordisk products: Ozempic, Wegovy, Saxenda)

1. Holographic foil panel on the side of the carton. Tilts and shifts when you angle the box. Counterfeit boxes often print a flat metallic ink that does not move under light.
2. Lot number printed on the carton. Matches the lot number on the pen itself. Both should look up cleanly on novocare.com (US) or the local Novo verification page.
3. Spelling. "Ozempic," "Wegovy," "semaglutide." A missing letter, a swapped O for a 0, or a doubled consonant is the most common counterfeit tell still in circulation.
4. Country-specific language and package insert. A box claiming to be Korean Wegovy should have Korean text on the carton and a Korean PIL inside. An English-only box sold in Seoul is a red flag regardless of where you bought it.
5. Manufacture and expiry dates printed cleanly, not over-stamped or smudged.

Box-level checks (Eli Lilly products: Mounjaro, Zepbound)

1. Single-dose pen format with a date and lot stamped on each individual pen. Counterfeit Mounjaro has been observed with mismatched lot numbers between the carton and individual pens.
2. Lot number lookup at lillyserialnumberlookup.com (US). Other markets have country-specific Lilly verification — your pharmacist can show you which.
3. Tamper-evident carton seal intact. Lilly cartons use a perforated tab. A clean, glued reseal is suspicious.

Pen-level checks (all GLP-1 injectors)

1. Clear cartridge with a visible solution. Real semaglutide and tirzepatide are clear, colorless to slightly yellow, and free of particles. Cloudy, turbid, off-white, or particle-containing solution should never be injected.
2. Pen mechanism feels firm, not loose. The dose dial clicks into discrete steps.
3. Label printed directly on the pen, not stickered on. A label that peels at the corner is a counterfeit fingerprint.
4. Needle attachment threading is consistent and the pen accepts the standard pen-needle for that brand.

Pharmacy and supply-chain checks

1. Bought from a state-licensed pharmacy. In the US, the NABP Verified Pharmacy site (safe.pharmacy) lists legitimate online sellers. In Korea, your prescription must be filled at a 약국. In the UK, GPhC-registered pharmacies only.
2. Real prescription required. This is the single biggest sorting filter. Any seller offering Wegovy, Ozempic, Mounjaro or Zepbound without a current prescription from a licensed prescriber is selling either a counterfeit or a stolen legitimate pen — neither is safe.
3. Price sanity check. US list price for Ozempic and Wegovy is roughly $900 to $1,000 per month. Mounjaro and Zepbound run roughly $1,000 to $1,300. Anything offered below about $200 a month outside Lilly Direct or NovoCare is a red flag, full stop. Coupons, manufacturer assistance and insurance can lower your out-of-pocket cost, but that lower price should come through a verifiable program, not a Telegram channel.
4. Cold-chain intact. GLP-1s ship and store at 2–8°C. A box arriving warm, or stored at room temperature for more than the manufacturer-permitted window, is a quality failure even if the contents are authentic.

A practical pre-injection checklist:

• Bought from a pharmacy licensed in my country.
• A licensed prescriber wrote the script.
• Cold chain held throughout shipping and storage.
• Carton tamper seal intact, no signs of resealing.
• Brand name and country language match what is approved in my market.
• Lot number on carton matches lot number on the pen.
• Lot number verifies on the manufacturer's lookup tool.
• Solution in the cartridge is clear and free of particles.
• Holographic foil (Novo) shifts under angle, label is printed not stickered (Lilly).
• Price paid is consistent with a legitimate pharmacy or manufacturer program.

Nine out of ten genuine prescriptions clear all ten boxes without effort. A counterfeit fails at least one — often three or four. The five-minute audit is not overcautious. It is the difference between an injection that loses you weight and an injection that ships you to the emergency department.

Where the official lookup tools live, by agency

Knowing the right tool is half the battle. A patient who knows where to verify a lot number takes about three minutes to do it. A patient who does not gives up and injects.

The regional tools differ but the underlying logic is identical. Every legitimate GLP-1 sold under a brand name has a registered SKU, a manufacturer-issued lot number, and a licensed pharmacy chain behind it. Every counterfeit fails on at least one of those three. The lookup tools exist for the patient to confirm — they were never designed for pharmacists alone.

Questions worth asking your doctor or pharmacist

Pharmacists know more about supply-chain integrity than almost anyone else in the system. They are also rarely asked about it directly. A few prompts that change the conversation:

• "Where does this specific pen come from in your wholesale chain?" Most legitimate US pharmacies source through one of three big wholesalers (McKesson, Cardinal Health, AmerisourceBergen) — and the pharmacist can name the chain. A vague answer is itself information.
• "Have any falsified semaglutide or tirzepatide alerts been issued in our country in the past 12 months?" Your pharmacist should know. If they do not, the pharmacy is not paying attention to the FDA / EMA / MHRA alert feeds it should be reading.
• "If I find a discrepancy on the lot number lookup, who do I report it to?" The answer should be specific — manufacturer hotline, national agency MedWatch or Yellow Card equivalent, and a return path to the pharmacy.
• "Is this a Medicare or insurance fill, a cash-pay fill from a manufacturer DTC program, or a cash-pay fill from another channel?" The first two are documented. The third needs to be a pharmacy you trust.
• "What does the pen look like if I open the box right now and you walk me through it?" A pharmacist who agrees to do this on the spot is the gold standard. One who refuses, or rushes you out the door, is worth a second thought.

For doctors specifically:

• "If supply tightens, do you have a verified-source backup channel — manufacturer DTC, hospital pharmacy, integrated health-system pharmacy?" The grey-market patients are usually the ones whose primary pharmacy ran out and who were left to improvise.
• "Will you write me a 90-day script if my insurance allows it, so I am not refilling monthly through whatever channel happens to be open?" Fewer refill events means fewer counterfeit-exposure events.

Pharmacists in 2024 hospital-admission cases in Hong Kong said the same thing in three separate interviews: the patients did not ask where the pen came from. They asked the price and they asked the dose. Nobody asked the supply chain question.

What to check before you buy or refill

If you are reading this before your next refill — that is the right time to use this. After the injection is too late.

For US patients:

1. Confirm your prescription source. State-licensed retail pharmacy, hospital pharmacy, manufacturer DTC (NovoCare, LillyDirect), or a NABP-Verified online pharmacy. If your seller is none of those four, stop.
2. Run the lot number on novocare.com (Novo products) or lillyserialnumberlookup.com (Lilly products) when the box arrives.
3. Cross-check pricing. List prices for Ozempic and Wegovy run $900–$1,000/month before insurance. Mounjaro and Zepbound run $1,000–$1,300. Manufacturer cash-pay programs (LillyDirect Zepbound starting at $349/month for boxed vials, NovoCare cash-pay options) sit in a defined band. Anything well below requires explanation.
4. Check the FDA drug shortage database. Tirzepatide came off the shortage list in December 2024; semaglutide came off in February 2025. Re-listing would be the earliest public signal that supply is tight again — and tight supply is when counterfeiters move volume.

For UK and EU patients:

1. Pharmacy must be GPhC-registered (UK), or the equivalent national pharmacy regulator across EU member states. Check the register before you buy.
2. Distance-selling pharmacies are legal but must display the EU common logo and link to the national regulator's verified-list page. No logo or no link means stop.
3. MHRA Yellow Card scheme accepts reports of suspected falsified medicines. National equivalents exist across the EU. File the report — it is what triggers the next national alert.

For patients in Korea, Japan and Hong Kong:

1. Korea: prescription only, dispensed at a 약국, and as of October 2024 overseas direct purchase (직구) of GLP-1 medications is banned outright. Anything bought through 직구 since that date is illegal regardless of authenticity, and customs has been seizing shipments at the border.
2. Japan: PMDA has flagged a rise in semaglutide imported for off-label cosmetic weight loss. If a Tokyo or Osaka clinic is offering ウゴービ or generic semaglutide without a documented obesity workup and PMDA-approved indication, the supply chain is a question mark.
3. Hong Kong: Drug Office issues prescription-medicine notices through the Department of Health. The 2024 hospital-admission cases involved unlicensed beauty centres dispensing fake "Ozempic." Licensed pharmacy plus a doctor's prescription remains the only safe route.

For patients in the Gulf:

1. Saudi Arabia: SFDA's Tatamman app verifies registered medicines by scanning the box. Use it. UAE has equivalent verification through MOHAP and the Dubai Health Authority.
2. Cash-pay private clinics are common across the region; the regulated ones operate inside licensed pharmacy channels. The unregulated ones often do not.
3. Distributor allocation lags global decisions by roughly a quarter. If the US tightens, Gulf shelves usually feel it 60 to 90 days later — which is also when grey-market substitutions tend to appear.

For patients in mainland China:

1. The legitimate brands are 诺和盈 (Wegovy), 诺和泰 (Ozempic) and 穆峰达 (Mounjaro). English-language packaging sold inside mainland China is a near-automatic counterfeit flag.
2. NMPA's drug-verification portal accepts the unique identifier on each box.
3. Hospital pharmacy is the safest channel; community pharmacies vary by region in how aggressively they vet wholesalers.

What this looks like in your market today

Reading the local texture as of April 2026:

United States. Counterfeit Ozempic remains the highest-volume confirmed threat. FDA alerts in 2023 and 2024 named specific lot numbers, but the scale of the parallel grey market means new fakes will keep surfacing. Wegovy and Zepbound counterfeits are a smaller but growing share. Lilly Direct's $349/month boxed-vial Zepbound program has materially reduced the cash-pay incentive to shop grey. NovoCare cash-pay options are similar. If you have a path to a manufacturer DTC program, it is the cleanest signal-to-noise channel available.

United Kingdom and EU. The MHRA, BfArM, FAMHP cluster of 2023–2024 alerts is the warning signal. NHS-channel Wegovy is essentially counterfeit-free; the risk concentrates in private slimming clinics that import from outside the EU GMP chain. The EU common logo on online pharmacy sites is a hard requirement, not a suggestion.

Korea. The October 2024 ban on 직구 of GLP-1s was the single biggest regulatory change for Korean patients in this cycle. It moved supply almost entirely back into the licensed 약국 channel. The remaining counterfeit risk concentrates in social-media private sellers and a small number of unlicensed cosmetic clinics. Mounjaro for obesity is off-label in Korea and supply has been tight since the August 2025 launch — which historically is when grey-market substitution accelerates. Stay in the licensed channel.

Japan. Cosmetic-clinic semaglutide is the watch-list segment. The legitimate ウゴービ pathway through PMDA-registered endocrinology and obesity clinics is intact; the import-and-inject cosmetic clinic segment is where PMDA advisories have concentrated through 2024–2026.

Hong Kong and Singapore. Both regulators have been aggressive — multiple counterfeit advisories from HSA, hospital admissions documented in HK. The licensed-pharmacy plus prescription path remains the only one that consistently clears. Beauty-centre dispensing is the avoidable failure mode.

Saudi Arabia and UAE. Public-awareness campaigns from SFDA and MOHAP through 2024–2025 reflect the volume of grey-market product surfacing in private cash-pay channels. Tatamman (Saudi) and the MOHAP licensed-pharmacy registry (UAE) are the practical verification tools. Use them at the pharmacy counter, not after you get home.

China mainland. NMPA prosecutions have hit the supply side of the counterfeit market. The patient-facing risk concentrates in English-packaged "Ozempic" sold through informal channels — usually a near-automatic counterfeit. The 诺和盈 / 诺和泰 / 穆峰达 SKUs through hospital pharmacy are the safe path.

Brazil. ANVISA warnings continued through 2024 after Brazil was named as a source country in WHO Alert N°6/2024. Hospital and licensed-farmácia channels are the way through; informal resellers shipping from neighbouring countries remain a documented risk.

If you want context on how shortages and grey-market activity track each other, our Medicare Wegovy global ripple breakdown walks the supply-allocation mechanics that drive the counterfeit market in the first place. Our big-pharma DTC access piece covers the manufacturer cash-pay channels — NovoCare and LillyDirect — that have done more to undercut counterfeit demand than any single enforcement action. And if you are weighing whether the side effects you are seeing on a refilled pen are normal versus a quality-control issue, the Wegovy side effects guide and the Mounjaro side effects guide are the side-effect baselines to compare against.

The five-minute audit at the kitchen counter — license, prescription, lot number, cold chain, label, solution, price — is not paranoia. It is the cheapest patient-safety intervention available right now. None of this is a substitute for talking to your prescribing clinician or pharmacist, but it is the homework worth doing before that conversation, not after. The next refill is the right time.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app